Patten & Patten’s Jazz Pharmaceuticals JAZZ Stock Holding History

Patten & Patten’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,575	Closed	-$230K	–	245
2017 Q3	$230K	Sell	1,575 -225	-13%	-$34K	0.02%	231
2017 Q2	$280K	Hold	1,800	–	–	0.03%	213
2017 Q1	$261K	Buy	+1,800	New	+$234K	0.03%	214
2016 Q4	–	Sell	-1,800	Closed	-$219K	–	224
2016 Q3	$219K	Hold	1,800	–	–	0.03%	201
2016 Q2	$254K	Sell	1,800 -300	-14%	-$44.2K	0.04%	192
2016 Q1	$274K	Hold	2,100	–	–	0.04%	186
2015 Q4	$295K	Buy	+2,100	New	+$291K	0.04%	185

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Patten & Patten's JAZZ Position: Q4 2017 in Review

Patten & Patten sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2017, closing a stake of 1,575 shares — an estimated $230K sold.

Patten & Patten first reported a position in JAZZ in Q4 2015 and held it in 7 quarters. The position peaked at $295K in Q4 2015. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

Patten & Patten reported no remaining Jazz Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Patten & Patten sold 1,575 Jazz Pharmaceuticals shares in Q4 2017, an estimated $230K.
Patten & Patten first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Patten & Patten's Jazz Pharmaceuticals position peaked at $295K in Q4 2015.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on Patten & Patten's 13F filing for Q4 2017, filed 22 Jan 2018.